PK/PD degli antibiotici utilizzati nella sepsi

Size: px
Start display at page:

Download "PK/PD degli antibiotici utilizzati nella sepsi"

Transcription

1 PK/PD degli antibiotici utilizzati nella sepsi Dario Cattaneo, U.O. Farmacologia Clinica ASST Fatebenefratelli Sacco, Milano Bergamo, città alta

2 Variability of antibiotic concentrations in critically ill patients Drug Trough concentration (mg/l)* Variability Meropenem 12.1 ( ) 6.7-fold Piperacillin ( ) 3.8-fold Tazobactam 3.8 ( ) 10.5-fold Vancomycin 12.0 ( ) 1.9-fold Ciprofloxacin 3.7 ( ) 3.9-fold *median (interquartile range) - Roberts, Crit Care Med How to explain such variability?!?

3 Common conditions: aging... Physiologic change Result PK parameter PK effect Reduced muscle mass and total water Accumulation of hydrophilic drugs Volume of distribution Increase of drug plasma concentrations Increased body fat Accumulation of lipophilic drugs Volume of distribution Increase of drug half-life - Klotz, Drug Metab Rev

4 Daptomycin AUC [linezolid], mg/l 500 ** Age quartiles [Linezolid] trough < 40 yrs 4.6 ± 4.9 mg/l yrs 6.1 ± 4.5 mg/l yrs 10.0 ± 7.0 mg/l** > 80 yrs 12.6 ± 9.3 mg/l** n= young (18-30 yr) geriatric (>75 yr) Patients age, yrs - Dvorchik, J Clin Pharmacol Cattaneo, IJAA 2016-

5 The issue of drug-to-drug interactions the inductive effect of rifapicin on linezolid metabolism may persist up to 2-3 weeks after stopping the drug Effects of rifampicin on cytochrome P450 (CYP) enzymes

6 Proton Pump inhibitors can increase the absorption of some antibiotics through inhibition of intestinal P-gp - Pea, AAC

7 In addition to these variables, critically ill patients may have also peculiar conditions that can affect the pharmacokinetics of antibiotics Critical illness - Roberts, Lancet Infect Dis

8 ..Augmented renal clearance can result in elevated renal elimination and subtherapeutic plasma concentrations, although whether this process solely involves augmented filtration or altered tubular secretion/reabsorption remains uncertain Antibacterials Drug CL in healthy subjects Drug CL in critically ill pts Cefpirome 102 ml/min 158 ml/min Ceftriaxone 19.8 ml/min 41 ml/min Ceftazidime 116 ml/min 125 ml/min Piperacillin 188 ml/min 396 ml/min Ertapenem 29.5 ml/min 200 ml/min. - Udy, Clin Pharmacokinet

9 In addition to these variables, critically ill patients may have also peculiar conditions that can affect the pharmacokinetics of antibiotics Critical illness - Roberts, Lancet Infect Dis

10 Changes in drug clearance for highly bound antibacterials in patients with hypoalbuminemia - Roberts, Clin Pharmacokinet

11 Highly bound (>70%) Moderately bound (70-30%) Minimally bound (<30%) Cefazolin Azithromycin Amikacin Cefoperazone Aztreonam Amoxicillin Ceftriaxone Cefotaxime Ampicillin Clindamicin Cefuroxime Cefepime Daptomycin Ciprofloxacin Ceftazidime Ertapenem Clarithromycin Doripenem Erythromycin Levofloxacin Gentamycin Minocycline Linezolid Imipenem Rifampicin Piperacillin Meropenem Teicoplanin Ticarcillin Norfloxacin Tigecycline Vancomycin Tobramycin - Ulldemolins, Clin Pharmacokinet

12 Volume of distribution (L) of b- lactam antibiotics in ICU patients Open circles: volume of distribution in healthy volunteers; filled squares: weighted means of volume of distribution in the studies; straight lines: ranges of the means of volume of distribution in the studies. V d = drug dose blood concentrations - Pereira, Critical Care

13 Lipophilic antibiotics *Extra Vd due to loss of fluids (capillary leakage) Negligible dilution 100 L Normal Vd High dilution Hydrophilic antibiotics Normal Vd Extra Vd* 10 L 4 L (Vd + 40%) 4 L (Vd + 4%) Extra Vd*

14 - Awad, CID

15 MIC MIC MIC MIC In VAP patients ceftobiprole elimination is increased by 40% and Vd is doubled... - Lagacé-Wiens, EODMT

16 In addition to these variables, critically ill patients may have also peculiar conditions that can affect the pharmacokinetics of antibiotics Critical illness - Roberts, Lancet Infect Dis

17 The pharmacokinetics of hydrophilic antibiotics is greatly altered in patients with renal insufficiency hydrophilic lipophilic

18 tigecycline - Mistry, J Clin Pharmacol Korth-Bradley, J Clin Pharmacol ertapenem

19 not everything is black or white... According to the USP monograph, the PKs of linezolid are not altered in patients with any degree of renal insufficiency - Cattaneo, Exp Opin Drug Metab Toxicol Sasaki, Antimicrob Agents Chemother

20 In addition to these variables, critically ill patients may have also peculiar conditions that can affect the pharmacokinetics of antibiotics Critical illness - Roberts, Lancet Infect Dis

21

22 1 st : 66-year-old man on PD since 2012 given linezolid to treat lumbar spondylodiscitis. This resulted in a progressive reduction in platelet count, reaching a nadir of cells/ml. Linezolid trough concentration: 25.5 mg/l. 2 nd : 74-year-old woman on PD since 2010 given linezolid for leg ulcers. Linezolid trough concentrations: 22.5 mg/l. 3 rd : 87-year-old woman on PD since 2013 given linezolid for Enterococcus faecalis peritonitis.the patient experienced pancytopenia and an increase in blood lactate values. Linezolid trough concentrations: 30 mg/l. 4 th : 57-year-old woman on PD since 2009 given linezolid for MDR Staphylococcus epidermidis peritonitis. Linezolid was withdrawn 20 days later due to severe pancytopenia. Three days later, the patient experienced severe lactic acidosis and was transferred to the ICU, where she died. A plasma sample collected nearly 90 h after stopping linezolid revealed a plasma concentration of 1.5 mg/l (estimated trough: mg/l).

23 E possibile quantificare il contributo di queste variabili nella pratica clinica? TDM is defined as the regular measurement of drugs concentrations requiring close 'titration' of doses in order to ensure that there are sufficient levels in the blood to be therapeutically effective, while avoiding potentially toxic excess

24 The issue of drug overexposure: the case of linezolid [Linezolid], mg/l Hematological Toxicity p = 0.01 No hematologic Toxicity - Cattaneo, Int J Antimicrob Agents Thrombocytopenia associated with [linezolid] >7 mg/l Thrombocytopenia associated with [linezolid] >8.2 mg/l - Pea, JAC Matsumoto Int J AA

25 Drug TDM target Amikacin C max mg/l Ciprofloxacin C min mg/l Colistin 2-5 mg/l Daptomycin C min <25 mg/l Gentamicin C min mg/l or C max 5-10 mg/l Levofloxacin C max 5-15 mg/l Linezolid C min 2-8 mg/l Meropenem - Piperacillin - Rifampicin C max 8-24 mg/l Sulfamethoxazole C max mg/l Tobramycin C max >10 mg/l or C min <1.0 mg/l Teicoplanin C min mg/l Trimethoprim C min 1-4 mg/l or C max 5-10 mg/l Vancomycin C min mg/l or C max mg/l - Jager, Exp Rev Clin Pharmacol

26 Oltre alla safety, esistono anche dei cutoff di concentrazioni anche per l efficacia???

27 ...for drugs that are C max /MIC-dependent you can measure C max for efficacy, and eventually C min for toxicity...

28 ...AUC/MIC-dependent... - Holmes, AAC AUC can be estimated with 2 blood samples (C min and C max )

29 ...Time>MIC-dependent... - Pea, IJAA2017 -

30 so in conclusion or, better to say, as starting point Giving the right dose is highly likely to increase the probability of clinical cure from infection and suppress the emergence of resistant pathogens. To enable optimized dosing, the use of customized dosing regimens through either evidence-based dosing nomograms or preferably through the use of dosing software supplemented by therapeutic drug monitoring data should be embedded into daily practice

Continuous Infusion of Antibiotics In The ICU: What Is Proven? Professor of Medicine Vice-Chairman, Department of Medicine SUNY at Stony Brook

Continuous Infusion of Antibiotics In The ICU: What Is Proven? Professor of Medicine Vice-Chairman, Department of Medicine SUNY at Stony Brook Continuous Infusion of Antibiotics In The ICU: What Is Proven? Michael S. Niederman, M.D. Chairman, Department of Medicine Winthrop-University Hospital Mineola, NY Professor of Medicine Vice-Chairman,

More information

AUGMENTED RENAL CLEARANCE and its clinical implications. Professor Jeffrey Lipman

AUGMENTED RENAL CLEARANCE and its clinical implications. Professor Jeffrey Lipman AUGMENTED RENAL CLEARANCE and its clinical implications Professor Jeffrey Lipman Department of Intensive Care Medicine Royal Brisbane Hospital University of Queensland Introduction Recommended dosages

More information

Lessons from recent studies. João Gonçalves Pereira UCIP DALI

Lessons from recent studies. João Gonçalves Pereira UCIP DALI Lessons from recent studies João Gonçalves Pereira UCIP DALI 1 Patterns of Antimicrobial Activity Concentration C max Aminoglycosides Cmax/MIC>10 Metronidazol Area under the concentration curve Azithromycin

More information

Is the package insert correct? PK considerations

Is the package insert correct? PK considerations Is the package insert correct? PK considerations Jason A Roberts B Pharm (Hons), PhD, FSHP Professor of Medicine and Pharmacy The University of Queensland, Australia Royal Brisbane and Women s Hospital,

More information

Professor of Chemotherapy Department of Preclinical and Clinical Pharmacology University of Florence

Professor of Chemotherapy Department of Preclinical and Clinical Pharmacology University of Florence Professor of Chemotherapy Department of Preclinical and Clinical Pharmacology University of Florence Researching field Pharmacokinetics, Pharmacodynamics of antimicrobial, antifungal and antitumoral drugs

More information

PHARMACOKINETIC & PHARMACODYNAMIC OF ANTIBIOTICS

PHARMACOKINETIC & PHARMACODYNAMIC OF ANTIBIOTICS PHARMACOKINETIC & PHARMACODYNAMIC OF ANTIBIOTICS SITI HIR HURAIZAH MD TAHIR Bpharm (UKM), MSc (Clinical Microbiology) (UoN) CLINICAL PHARMACIST HOSPITAL MELAKA WHY STUDY PHARMACOKINETICS (PK) AND PHARMACODYNAMICS

More information

Drug Management in CRRT

Drug Management in CRRT Drug Management in CRRT Jeffrey Lipman, FCICM, MD Department of Intensive Care Medicine Royal Brisbane Hospital University of Queensland Bruce A. Mueller, PharmD, FCCP, FASN Clinical, Social & Administrative

More information

A Snapshot of Colistin Use in South-East Europe and Particularly in Greece

A Snapshot of Colistin Use in South-East Europe and Particularly in Greece A Snapshot of Colistin Use in South-East Europe and Particularly in Greece Helen Giamarellou 02.05.2013 When Greek Physicians Prescribe Colistin? It is mainly prescribed in the ICU for VAP, bacteremia

More information

Therapeutic drug monitoring of β-lactams

Therapeutic drug monitoring of β-lactams CORATA Belgique Reims 1-2/10/2014 Therapeutic drug monitoring of β-lactams Frédéric Cotton Clinical Chemistry Erasme Hospital Faculty of Pharmacy ULB TDM of β-lactams β-lactams pharmacokinetics pharmacodynamics

More information

Should we be performing TDM in seriously ill patients with Gram negative infections?

Should we be performing TDM in seriously ill patients with Gram negative infections? Should we be performing TDM in seriously ill patients with Gram negative infections? Jason A Roberts B Pharm (Hons), PhD, FSHP Royal Brisbane and Women s Hospital, Australia. The University of Queensland,

More information

La farmacologia in aiuto

La farmacologia in aiuto Ferrara, 15 giugno 2018 La farmacologia in aiuto Pier Giorgio Cojutti, Federico Pea Istituto di Farmacologia Clinica Azienda Sanitaria Universitaria Integrata di Udine Therapeutic Drug Monitoring of Beta-Lactams

More information

Medication Dosing in CRRT

Medication Dosing in CRRT Medication Dosing in CRRT Linda Awdishu, PharmD, MAS Associate Clinical Professor of Pharmacy and Medicine Learning Objectives 1. List the pharmacokinetic changes associated with AKI. 2. Determine the

More information

EXTRACORPOREAL TECHNIQUES IN MODS: An Update :Techniques For Organ Support Where Are We In 2013? Prof Patrick Honoré,MD, PhD, Intensivist-Nephrologist

EXTRACORPOREAL TECHNIQUES IN MODS: An Update :Techniques For Organ Support Where Are We In 2013? Prof Patrick Honoré,MD, PhD, Intensivist-Nephrologist EXTRACORPOREAL TECHNIQUES IN MODS: An Update :Techniques For Organ Support Where Are We In 2013? 1.-CRRT : A «Lego» Module? 4.-Antibiotic Adaptation During Low Dose CRRT? 2.- CRRT + ECMO: What to do? 5.-

More information

Drug Typical Dose CrCl (ml/min) Dose adjustment for renal insufficiency Acyclovir PO (HSV) 400 mg TID >10 <10 or HD PD

Drug Typical Dose CrCl (ml/min) Dose adjustment for renal insufficiency Acyclovir PO (HSV) 400 mg TID >10 <10 or HD PD Antimicrobial Dosing in Renal Insufficiency (Adults) ASP Handbook * In patients on hemodialysis (), give antimicrobial immediately after dialysis on dialysis days. = Intermittent hemodialysis = Peritoneal

More information

ICU Volume 11 - Issue 3 - Autumn Series

ICU Volume 11 - Issue 3 - Autumn Series ICU Volume 11 - Issue 3 - Autumn 2011 - Series Impact of Pharmacokinetics of Antibiotics in ICU Clinical Practice Introduction The efficacy of a drug is mainly dependent on its ability to achieve an effective

More information

ZIN EN ONZIN VAN ANTIBIOTICASPIEGELS BIJ NEONATEN

ZIN EN ONZIN VAN ANTIBIOTICASPIEGELS BIJ NEONATEN ZIN EN ONZIN VAN ANTIBIOTICASPIEGELS BIJ NEONATEN Anne Smits Fellow neonatologie UZ Leuven Use of antibiotics in neonates 50 European hospitals 23 non-european hospitals Countries n = 14 n = 9 Pediatric

More information

Optimizing Antibiotic Therapy in the ICU For Pneumonia Current and Future Approaches

Optimizing Antibiotic Therapy in the ICU For Pneumonia Current and Future Approaches Optimizing Antibiotic Therapy in the ICU For Pneumonia Current and Future Approaches Andrew F. Shorr, MD, MPH Washington Hospital Center Georgetown Univ. Disclosures I have served as a consultant to, researcher/investigator

More information

Antimicrobial Reference Laboratory

Antimicrobial Reference Laboratory Antimicrobial Reference Laboratory GUIDELINE RANGES FOR TDM 2018 Andrew Lovering Antimicrobial Reference Laboratory North Bristol NHS Trust Southmead Hospital Bristol, BS10 5NB Guideline Ranges 2018 Aminoglycosides

More information

Antimicrobial Reference Laboratory

Antimicrobial Reference Laboratory Antimicrobial Reference Laboratory GUIDELINE RANGES FOR TDM 2016-17 Andrew Lovering Antimicrobial Reference Laboratory North Bristol NHS Trust Southmead Hospital Bristol, BS10 5NB UK Aminoglycosides Gentamicin

More information

The general Concepts of Pharmacokinetics

The general Concepts of Pharmacokinetics The general Concepts of Pharmacokinetics What is this jargon? Is it useful? C max, clearance, Vd, half-life, AUC, bioavailability, protein binding F. Van Bambeke, E. Ampe, P.M. Tulkens (Université catholique

More information

Laboratory CLSI M100-S18 update. Paul D. Fey, Ph.D. Associate Professor/Associate Director Josh Rowland, M.T. (ASCP) State Training Coordinator

Laboratory CLSI M100-S18 update. Paul D. Fey, Ph.D. Associate Professor/Associate Director Josh Rowland, M.T. (ASCP) State Training Coordinator Nebraska Public Health Laboratory 2008 CLSI M100-S18 update Paul D. Fey, Ph.D. Associate Professor/Associate Director Josh Rowland, M.T. (ASCP) State Training Coordinator Agenda Discuss 2008 M100- S18

More information

This letter authorises the extended use of the following guidance until 1st December 2018:

This letter authorises the extended use of the following guidance until 1st December 2018: NHS Grampian Westholme Woodend Hospital Queens Road ABERDEEN AB15 6LS NHS Grampian Date 29 1h May 2018 Our Ref FApenicillin/hype/MGPG/May 18 Enquiries to Frances Adamson Extension 56689 Direct Line 01224

More information

Expert rules. for Gram-negatives

Expert rules. for Gram-negatives Academic Perspective in Expert rules Emerging Issues of Resistance in Gram-ve Bacteria for Gram-negatives Trevor Winstanley Sheffield Teaching Hospitals Presented on behalf of David Livermore University

More information

Disclosures. Efficacy of the drug. Optimizing Dosing Based on PKPD- An overview. Dose Finding - The Past

Disclosures. Efficacy of the drug. Optimizing Dosing Based on PKPD- An overview. Dose Finding - The Past Disclosures Optimizing Dosing Based on PKPD- An overview Johan W. Mouton MD PhD FIDSA FAAM Professor pharmacokinetics and pharmacodynamics Research grants advisory boards speaker This Patient Needs Antibiotics.

More information

The antibiotic dose and the obese ICU patient

The antibiotic dose and the obese ICU patient The antibiotic dose and the obese ICU patient Philippe Montravers, M.D., Ph.D. Anaesthesia and Surgical ICU CHU Bichat Claude Bernard Assistance Publique-Hôpitaux de Paris INSERM UMR 1152 University Paris

More information

PHA Spring First Exam. 8 Aminoglycosides (5 points)

PHA Spring First Exam. 8 Aminoglycosides (5 points) PHA 5128 Spring 2012 First Exam 1 Aminoglycosides (5 points) 2 Aminoglycosides (10 points) 3 Basic Principles (5 points) 4 Basic Principles (5 points) 5 Bioavailability (5 points) 6 Vancomycin (5 points)

More information

ANTIBIOTIC DOSE AND DOSE INTERVALS IN RRT and ECMO

ANTIBIOTIC DOSE AND DOSE INTERVALS IN RRT and ECMO ANTIBIOTIC DOSE AND DOSE INTERVALS IN RRT and ECMO Professor Jeffrey Lipman Department of Intensive Care Medicine Royal Brisbane Hospital University of Queensland NO CONFLICT OF INTERESTS Important concept

More information

Adult Inpatient Antibiogram. Antimicrobial Susceptibilities of Frequently Recovered Clinical Isolates. January to December 2016

Adult Inpatient Antibiogram. Antimicrobial Susceptibilities of Frequently Recovered Clinical Isolates. January to December 2016 Adult Inpatient Antibiogram Antimicrobial Susceptibilities of Frequently Recovered Clinical Isolates January to December 2016 Department of Pathology Camille Hamula, PhD Director, Clinical Microbiology

More information

Pharmacodynamic indices in targeting therapy of critical infections

Pharmacodynamic indices in targeting therapy of critical infections Pharmacodynamic indices in targeting therapy of critical infections P.M. Tulkens Cellular and Molecular Pharmacology, Catholic University of Louvain, Brussels, Belgium & International Society of Anti-infective

More information

Pharmacokinetics pharmacodynamics issues relevant for the clinical use of betalactam antibiotics in critically ill patients

Pharmacokinetics pharmacodynamics issues relevant for the clinical use of betalactam antibiotics in critically ill patients Veiga and Paiva Critical Care (2018) 22:233 https://doi.org/10.1186/s13054-018-2155-1 REVIEW Pharmacokinetics pharmacodynamics issues relevant for the clinical use of betalactam antibiotics in critically

More information

Alterazioni farmacocinetiche e farmacodinamiche (PK/PD) associate all età

Alterazioni farmacocinetiche e farmacodinamiche (PK/PD) associate all età Alterazioni farmacocinetiche e farmacodinamiche (PK/PD) associate all età Dario Cattaneo, U.O. Farmacologia Clinica Az. Ospedaliera Polo Universitario L. Sacco, Milano Bergamo, città alta ..ma è davvero

More information

MIC Test Strip for antimicrobial susceptibility testing

MIC Test Strip for antimicrobial susceptibility testing for antimicrobial susceptibility testing Liofilchem Liofilchem Quantitative assay for determining the Minimum Inhibitory Concentration (M.I.C.) is a quantitative assay for determining the Minimum Inhibitory

More information

Dilemmas in Septic Shock

Dilemmas in Septic Shock Dilemmas in Septic Shock William Janssen, M.D. Assistant Professor of Medicine National Jewish Health University of Colorado Denver Health Sciences Center A 62 year-old female presents to the ED with fever,

More information

prophylaxis for endocarditis in patients at high risk prophylaxis for major surgical procedures

prophylaxis for endocarditis in patients at high risk prophylaxis for major surgical procedures 1 Glycopeptides appropriate uses serious infections due to beta-lactam- resistant gram-positive microorganisms infections due to gram-positive microorganisms in patients with serious allergy to beta-lactam

More information

Increased dosing of β-lactams = Increased Toxicity?

Increased dosing of β-lactams = Increased Toxicity? Increased dosing of β-lactams = Increased Toxicity? Dr Marjorie Beumier Intensive Care department Dr Beumier- Soins Hôpital intensifs Ambroise Hôpital Paré Ambroise Paré β-lactams Standard dosing = Wide

More information

Antibiotic Dosing in the Elderly

Antibiotic Dosing in the Elderly Antibiotic Dosing in the Elderly Philip Chung, PharmD, MS, BCPS Nebraska ASAP Community Network Pharmacy Coordinator Nebraska Medicine Disclosure I have no relevant disclosure The presentation includes

More information

Practical issues - dosing on extracorporeal circuits

Practical issues - dosing on extracorporeal circuits Practical issues - dosing on extracorporeal circuits Jason A Roberts B Pharm (Hons), PhD, FSHP Professor of Medicine and Pharmacy The University of Queensland, Australia Royal Brisbane and Women s Hospital,

More information

Antibiotic Resistance Pattern of Blood and CSF Culture Isolates At NHLS Academic Laboratories (2005)

Antibiotic Resistance Pattern of Blood and CSF Culture Isolates At NHLS Academic Laboratories (2005) Antibiotic Resistance Pattern of Blood and CSF Culture Isolates At NHLS Academic Laboratories (2005) Streptococcus pneumoniae (SP) Blood Culture Isolates Penicillin intermediate Penicillin Cefotaxime 336

More information

Both adult and pediatric* 24 (46% of 52 members) Region: New England 51 (48% of 107 members) 45 (52% of 87 members) 29 (47% of 62 members)

Both adult and pediatric* 24 (46% of 52 members) Region: New England 51 (48% of 107 members) 45 (52% of 87 members) 29 (47% of 62 members) Infectious Diseases Society of America Emerging Infections Network Report for Query: Antimicrobial Drug Shortages 2016 Overall response rate: 701/1,597 (44%) physicians responded from 3/22/16 to 4/13/16.

More information

Development of C sporins. Beta-lactam antibiotics - Cephalosporins. Second generation C sporins. Targets - PBP s

Development of C sporins. Beta-lactam antibiotics - Cephalosporins. Second generation C sporins. Targets - PBP s Beta-lactam antibiotics - Cephalosporins Development of C sporins Targets - PBP s Activity - Cidal - growing organisms (like the penicillins) Principles of action - Affinity for PBP s Permeability properties

More information

5 Infections. To be used in conjunction with NICE guidance, The British National Formulary for adults and/or children and

5 Infections. To be used in conjunction with NICE guidance, The British National Formulary for adults and/or children and 5 Infections To be used in conjunction with NICE guidance, The British National Formulary for adults and/or children and Southend University Hospital, Antibiotic Guidelines Index 5.1 Antibacterial drugs

More information

Sepsis new definitions of sepsis and septic shock and Novelities in sepsis treatment

Sepsis new definitions of sepsis and septic shock and Novelities in sepsis treatment Sepsis new definitions of sepsis and septic shock and Novelities in sepsis treatment What is sepsis? Life-threatening organ dysfunction caused by a dysregulated host response to infection A 1991 consensus

More information

Terapia delle infezioni da Pseudomonas aeruginosa MDR

Terapia delle infezioni da Pseudomonas aeruginosa MDR Verona 23 ottobre 2010 Terapia delle infezioni da Pseudomonas aeruginosa MDR Pierluigi Viale Clinica di Malattie Infettive Policlinico S. Orsola Malpighi Global resistance surveillance of Pseudomonas aeruginosa

More information

Continuous vs Intermittent Dosing of Antibiotics in Critically-Ill Patients

Continuous vs Intermittent Dosing of Antibiotics in Critically-Ill Patients Continuous vs Intermittent Dosing of Antibiotics in Critically-Ill Patients Jan O Friedrich, MD DPhil Associate Professor of Medicine, University of Toronto Medical Director, MSICU St. Michael s Hospital,

More information

Urinary Tract Infections: From Simple to Complex. Adriane N Irwin, MS, PharmD, BCACP Clinical Assistant Professor Ambulatory Care October 25, 2014

Urinary Tract Infections: From Simple to Complex. Adriane N Irwin, MS, PharmD, BCACP Clinical Assistant Professor Ambulatory Care October 25, 2014 Urinary Tract Infections: From Simple to Complex Adriane N Irwin, MS, PharmD, BCACP Clinical Assistant Professor Ambulatory Care October 25, 2014 Learning Objectives Develop empiric antimicrobial treatment

More information

Academic Perspective in. David Livermore Prof of Medical Microbiology, UEA Lead on Antibiotic resistance PHE

Academic Perspective in. David Livermore Prof of Medical Microbiology, UEA Lead on Antibiotic resistance PHE Academic Perspective in Emerging No, we can t Issues treat of carbapenemase Resistance and ESBL in Gram-ve producers Bacteria based on MIC David Livermore Prof of Medical Microbiology, UEA Lead on Antibiotic

More information

Expert rules in antimicrobial susceptibility testing: State of the art

Expert rules in antimicrobial susceptibility testing: State of the art Expert rules in antimicrobial susceptibility testing: State of the art ESCMID Postgraduate Education Course Antimicrobial Susceptibility Testing and Surveillance: from Laboratory to Clinic Hospital Universitario

More information

ESCMID Online Lecture Library. by author

ESCMID Online Lecture Library. by author Novel PK/PD data on the optimisation of colistin and the carbapenems Diamantis Plachouras Athens, Greece Hot Topics on Infections in the Critically Ill Patient, ESCMID Postgraduate Education Course, 31

More information

Adult Dose. Adults Day 1: 1mg/kg daily Day 2: 2mg/kg daily Day 3 onwards: 3mg/kg daily. Where appropriate consider rounding dose to nearest 50mg.

Adult Dose. Adults Day 1: 1mg/kg daily Day 2: 2mg/kg daily Day 3 onwards: 3mg/kg daily. Where appropriate consider rounding dose to nearest 50mg. AMIKACIN All ages>1month: 30mg/kg daily 1.5g once daily IV infusion over 30-60 Monitor renal function before treatment and weekly. Caution if used with other nephrotoxic drugs. Levels required. Trough

More information

Towards clinical Applications of PK-PD in specific situations

Towards clinical Applications of PK-PD in specific situations Towards clinical Applications of PK-PD in specific situations P.M. Tulkens Cellular and Molecular Pharmacology & Center for Clinical Pharmacy, Catholic University of Louvain, Brussels, Belgium with many

More information

Paul M. Tulkens Françoise Van Bambeke. Unité de pharmacologie cellulaire et moléculaire & Louvain Drug Research Institute

Paul M. Tulkens Françoise Van Bambeke. Unité de pharmacologie cellulaire et moléculaire & Louvain Drug Research Institute New antimicrobials Paul M. Tulkens Françoise Van Bambeke Unité de pharmacologie cellulaire et moléculaire & Louvain Drug Research Institute Université catholique de Louvain,, Brussels, Belgium Slides are

More information

GUIDELINES FOR USERS ANTIMICROBIAL REFERENCE LABORATORY ASSAY SERVICE. 17th Edition

GUIDELINES FOR USERS ANTIMICROBIAL REFERENCE LABORATORY ASSAY SERVICE. 17th Edition ANTIMICROBIAL REFERENCE LABORATORY ASSAY SERVICE GUIDELINES FOR USERS 17th Edition 2011 Earlier editions should be destroyed Antimicrobial Reference Laboratory Department of Medical Microbiology North

More information

ESCMID Online Lecture Library. by author

ESCMID Online Lecture Library. by author Hospital Universitario Virgen Macarena, Seville New drugs against MRSA and VRE L. Eduardo López Cortés Seville, 8th July Tedizolid Oxazolidinone Ceftaroline // Ceftobiprole 5 th gen cephalosporin Overview

More information

Panel discussion-aidc 2017 Rapport with the microbiology lab-how it helps your patient

Panel discussion-aidc 2017 Rapport with the microbiology lab-how it helps your patient Panel discussion-aidc 2017 Rapport with the microbiology lab-how it helps your patient Dr Ram Gopalakrishnan Dr S Nandini Moderator Dr V R Yamunadevi Scenario 1 60 year old male patient admitted in ICU

More information

Other β-lactam. A. Carbapenems:

Other β-lactam. A. Carbapenems: A. Carbapenems: Other β-lactam Carbapenems are synthetic β-lactam antibiotics Differ in structure from the penicillins in that the sulfur atom of the thiazolidine ring. Imipenem, meropenem, doripenem,

More information

Current challenges in triazole TDM

Current challenges in triazole TDM Current challenges in triazole TDM Isabel Spriet, PharmD PhD Clinical Pharmacology and Pharmacotherapy, University Hospitals Leuven & KU Leuven, Belgium Background Triazoles are the most widely prescribed

More information

ADULT ANTIMICROBIAL DOSING TOOL (NB Provincial Health Authorities Anti-Infective Stewardship Committee, September 2017)

ADULT ANTIMICROBIAL DOSING TOOL (NB Provincial Health Authorities Anti-Infective Stewardship Committee, September 2017) (NB Provincial Health Authorities Anti-Infective Stewardship Committee, September 2017) Introduction The dosing recommendations presented here are for adults with moderate-to-severe infections and are

More information

Linezolid - Tigecycline

Linezolid - Tigecycline Linezolid - Tigecycline Paul M. Tulkens, MD, PhD Cellular and Molecular Pharmacology Louvain Drug Research Institute Catholic University of Louvain, Brussels, Belgium With the support of Wallonie-Bruxelles-International

More information

PREVENTION AND TREATMENT OF BACTERIAL INFECTIONS IN CIRRHOSIS

PREVENTION AND TREATMENT OF BACTERIAL INFECTIONS IN CIRRHOSIS PREVENTION AND TREATMENT OF BACTERIAL INFECTIONS IN CIRRHOSIS Dr. J. Fernández. Head of the Liver Unit Hospital Clinic Barcelona, Spain AEEH Postgraduate Course, Madrid, February 15 2017 Prevalence of

More information

What is new in EUCAST South Africa, May, Gunnar Kahlmeter EUCAST Technical Data Coordinator and Webmaster Sweden

What is new in EUCAST South Africa, May, Gunnar Kahlmeter EUCAST Technical Data Coordinator and Webmaster Sweden What is new in EUCAST 2016 17 South Africa, May, 2016 Gunnar Kahlmeter EUCAST Technical Data Coordinator and Webmaster Sweden What is new in EUCAST 2016/17? New organisms with breakpoints (Addendum 2016)

More information

Mortality Rate was unsightly!!! 4/24/2013. Sepsis Quality Improvement Project

Mortality Rate was unsightly!!! 4/24/2013. Sepsis Quality Improvement Project Libby, MT Sepsis Quality Improvement Project Barb Dumont RN, Director of Quality and Risk Management Mike Julius RN, ED Manager Cathy Wolfe RN, Chief Nursing Officer. Mortality Rate was unsightly!!! percent

More information

Diane M. Gomes, Pharm.D. Outcomes in Antimicrobial Stewardship Post-Doctoral Pharmacy Fellow Providence Veterans Affairs Medical Center

Diane M. Gomes, Pharm.D. Outcomes in Antimicrobial Stewardship Post-Doctoral Pharmacy Fellow Providence Veterans Affairs Medical Center Diane M. Gomes, Pharm.D. Outcomes in Antimicrobial Stewardship Post-Doctoral Pharmacy Fellow Providence Veterans Affairs Medical Center The information disseminated in this lecture is given in my personal

More information

2019 PHP PRIMARY CARE INCENTIVE

2019 PHP PRIMARY CARE INCENTIVE Primary Care Physicians (PCP) of Physicians Health Network (PHN) may be eligible for an incentive payment in accordance with this PHP PCP Incentive (hereinafter referred to as the PCP Incentive ). As described

More information

Drug dosing in Extremes of Weight

Drug dosing in Extremes of Weight Drug dosing in Extremes of Weight The Plump & Heavy versus The Skinny & Light Maria Minerva P. Calimag, MD, MSc, PhD, DPBA, FPSECP PROFESSOR Departments of Pharmacology, Anesthesiology and Clinical Epidemiology

More information

Treatment of Tuberculosis Therapeutic Drug Monitoring

Treatment of Tuberculosis Therapeutic Drug Monitoring Treatment of Tuberculosis Therapeutic Drug Monitoring 2nd European Advanced Course in Clinical Tuberculosis Dr. JWC Alffenaar, clinical pharmacologist Dept Clinical Pharmacy & Pharmacology University Medical

More information

December 3, 2015 Severe Sepsis and Septic Shock Antibiotic Guide

December 3, 2015 Severe Sepsis and Septic Shock Antibiotic Guide Severe Sepsis and Septic Shock Antibiotic Guide Surviving Sepsis: The choice of empirical antimicrobial therapy depends on complex issues related to the patient s history, including drug intolerances,

More information

Basic Concepts of PK/PD -pharmacodynamic indices- Johan W. Mouton MD PhD FIDSA Professor pharmacokinetics and pharmacodymamics

Basic Concepts of PK/PD -pharmacodynamic indices- Johan W. Mouton MD PhD FIDSA Professor pharmacokinetics and pharmacodymamics Basic Concepts of PK/PD -pharmacodynamic indices- Johan W. Mouton MD PhD FIDSA Professor pharmacokinetics and pharmacodymamics This patient needs antibiotics. But which ones? Intensive care patient Ceftazidime,

More information

ESCMID Online Lecture Library. by author

ESCMID Online Lecture Library. by author www.eucast.org EXPERT RULES IN ANTIMICROBIAL SUSCEPTIBILITY TESTING Dr. Rafael Cantón Hospital Universitario Ramón y Cajal SERVICIO DE MICROBIOLOGÍA Y PARASITOLOGÍA Departamento de Microbiología II Universidad

More information

Use of Antibacterial Agents in Renal Failure

Use of Antibacterial Agents in Renal Failure Use of Antibacterial Agents in Renal Failure Brett Gilbert, DO a, *, Paul Robbins, DO b, Lawrence L. Livornese Jr, MD, FIDSA c KEYWORDS Antibiotics Renal failure Volume of distribution MDRD Dosing antibiotics

More information

PHA 5127 FINAL EXAM FALL On my honor, I have neither given nor received unauthorized aid in doing this assignment.

PHA 5127 FINAL EXAM FALL On my honor, I have neither given nor received unauthorized aid in doing this assignment. PHA 5127 FINAL EXAM FALL 1997 On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name Question Points 1. /14 pts 2. /10 pts 3. /8 pts 4 /8 pts 5. /12 pts 6. /8 pts

More information

Counties in the top and bottom two quintiles of both diabetes and obesity, Age-adjusted percentage of adults aged 20 years who are obese, 2007

Counties in the top and bottom two quintiles of both diabetes and obesity, Age-adjusted percentage of adults aged 20 years who are obese, 2007 Impact of Obesity on Medication Dosing John C. Williamson, PharmD, BCPS, AAHIVE Wake Forest University Baptist Medical Center Winston-Salem, NC Objectives Determine what constitutes the various forms of

More information

Aminoglycosides John A. Bosso, Pharm.D.

Aminoglycosides John A. Bosso, Pharm.D. AMINOGLYCOSIDES Therapeutics/PHRMP-73 Aminoglycoside Mechanism of Action Aminoglycosides bind to 30s ribosomal subunit resulting in mistranslation of mrna thus disrupting protein synthesis. They are rapidly

More information

Severe β-lactam allergy. Alternative (use for mild-moderate β-lactam allergy) therapy

Severe β-lactam allergy. Alternative (use for mild-moderate β-lactam allergy) therapy Recommended Empirical Antibiotic Regimens for MICU Patients Notes: The antibiotic regimens shown are general guidelines and should not replace clinical judgment. Always assess for antibiotic allergies.

More information

HUSRES Annual Report 2009 Martti Vaara

HUSRES Annual Report 2009 Martti Vaara HUSRES Annual Report 2009 Martti Vaara www.huslab.fi www.intra.hus.fi Martti Vaara, 2/2010 1 The basis of this HUSRES 2009 report is the HUSLAB/Whonet database 2009, which contains susceptibility data

More information

Pharmacologyonline 1: (2010) ewsletter Singh and Kochbar. Optimizing Pharmacokinetic/Pharmacodynamics Principles & Role of

Pharmacologyonline 1: (2010) ewsletter Singh and Kochbar. Optimizing Pharmacokinetic/Pharmacodynamics Principles & Role of Optimizing Pharmacokinetic/Pharmacodynamics Principles & Role of Cefoperazone Sulbactam Singh M*, Kochhar P* Medical & Research Division, Pfizer India. Summary Antimicrobial resistance is associated with

More information

Dry injection list 1-Ceftriaxone 1000 mg & Sulbactam 500 mg Inj. 2-Ceftriaxone 500 mg & Sulbactam 250 mg Inj.

Dry injection list 1-Ceftriaxone 1000 mg & Sulbactam 500 mg Inj. 2-Ceftriaxone 500 mg & Sulbactam 250 mg Inj. Dry injection list 1-Ceftriaxone 1000 mg & Sulbactam 500 mg Inj. 2-Ceftriaxone 500 mg & Sulbactam 250 mg Inj. 3-Ceftriaxone 250mg & Sulbactam 125mg Inj. 4-Ceftriaxone 125mg & Sulbactam 62.5mg Inj. 5-Rabeprazole

More information

Johan W. Mouton MD PhD FIDSA Professor pharmacokinetics and pharmacodynamics

Johan W. Mouton MD PhD FIDSA Professor pharmacokinetics and pharmacodynamics Exposure - Response Johan W. Mouton MD PhD FIDSA Professor pharmacokinetics and pharmacodynamics ACTVITY in vitro (MIC) CONCENTRATIONS in vivo (PK) DOSING regimen Other factors ANTMICROBIAL EFFICACY (Microbiological

More information

SBUH Aminoglycoside Dosing Protocol

SBUH Aminoglycoside Dosing Protocol Adult Aminoglycoside Dosing for Gram negative infections prior to available serum levels (Excludes patients with cystic fibrosis, OB GYN patients and surgical prophylaxis) Cr Cl 40 ml/min 5 7 mg/kg INT

More information

Cubicin A Guide to Dosing

Cubicin A Guide to Dosing Cubicin A Guide to Dosing Cubicin (Daptomycin) powder for solution for injection or infusion Indications (see SmPC) 1 : Cubicin is indicated for the treatment of the following infections (see sections

More information

Healthy Adult cuti Patient. Cmax (mcg/ml)(mean ± SD) 73.7 ± ± 113. Vd (L)(mean ± SD) 17.9 ± ± 12.1

Healthy Adult cuti Patient. Cmax (mcg/ml)(mean ± SD) 73.7 ± ± 113. Vd (L)(mean ± SD) 17.9 ± ± 12.1 Brand Name: Zemdri Generic Name: plazomicin Manufacturer: Achaogen, Inc Drug Class: aminoglycoside antibacterial Uses: 1-5 Labeled: treatment of complicated urinary tract infections (cuti), including pyelonephritis,

More information

RGH E-Bulletin Digest Number 51

RGH E-Bulletin Digest Number 51 RGH E-Bulletin Digest Number 51 The next in our 2012 series of continuing education activities is the RGH E-Bulletin Digest No. 50 edited by Associate Professor Chis Alderman. This CE activity assesses

More information

Giving the Proper Dose: How Can The Clinical and Laboratory Standards Institute(CLSI)Help?

Giving the Proper Dose: How Can The Clinical and Laboratory Standards Institute(CLSI)Help? Giving the Proper Dose: How Can The Clinical and Laboratory Standards Institute(CLSI)Help? Pranita D. Tamma, M.D., M.H.S. Director, Pediatric Antimicrobial Stewardship Johns Hopkins University School of

More information

Pharmacokinetics and safety of Moxifloxacin: Preliminary results of a dose escalation study

Pharmacokinetics and safety of Moxifloxacin: Preliminary results of a dose escalation study Pharmacokinetics and safety of Moxifloxacin: Preliminary results of a dose escalation study A.D. Pranger 1, W.C.M. de Lange 2, R. van Altena 2, P. van der Harst 3, M.P. van den Berg 3, D.R.A. Uges 1, J.G.W.

More information

CRRT and Drug dosing. Karlee Johnston Lead Pharmacist Division of Critical Care ICU Education June 2017

CRRT and Drug dosing. Karlee Johnston Lead Pharmacist Division of Critical Care ICU Education June 2017 CRRT and Drug dosing Karlee Johnston Lead Pharmacist Division of Critical Care ICU Education June 2017 This talk In scope CRRT modalities with regard to medicine Principles of drugs with regard to dialysis

More information

Vancomycin Pharmacokinetics. Myrna Y. Munar, Pharm.D., BCPS Associate Professor of Pharmacy

Vancomycin Pharmacokinetics. Myrna Y. Munar, Pharm.D., BCPS Associate Professor of Pharmacy Vancomycin Pharmacokinetics Myrna Y. Munar, Pharm.D., BCPS Associate Professor of Pharmacy Goals Review the PK properties of vancomycin Compare and contrast methods of dosage regimen design for vancomycin

More information

Therapy of MDR/XDR Gram-negative bacteria: dealing with the devil. CRE: high dosing, how much? by author

Therapy of MDR/XDR Gram-negative bacteria: dealing with the devil. CRE: high dosing, how much? by author Therapy of MDR/XDR Gram-negative bacteria: dealing with the devil CRE: high dosing, how much? George L. Daikos, MD National and Kapodistrian University of Athens, Laiko General Hospital, Athens, Greece

More information

Pharmacokinetics of daptomycin in a patient with severe renal failure not under dialysis

Pharmacokinetics of daptomycin in a patient with severe renal failure not under dialysis AAC Accepts, published online ahead of print on 1 April 2013 Antimicrob. Agents Chemother. doi:10.1128/aac.00230-13 Copyright 2013, American Society for Microbiology. All Rights Reserved. 1 Pharmacokinetics

More information

Pharmacologyonline 3: (2009) ewsletter Singh et al.

Pharmacologyonline 3: (2009) ewsletter Singh et al. USE OF CEFOPERAZO E - SULBACTAM 2:1 I PATIE TS WITH COMPROMISED RE AL FU CTIO Singh M*, Kochhar P*, Suvarna V*, Patel A** * Medical & Research Division, Pfizer India. ** Infectious Diseases Clinic, "VEDANTA"

More information

Treatment of prosthetic joint infection. Alex Soriano Department of Infectious Diseases Hospital Clínic of Barcelona

Treatment of prosthetic joint infection. Alex Soriano Department of Infectious Diseases Hospital Clínic of Barcelona Treatment of prosthetic joint infection Alex Soriano Department of Infectious Diseases Hospital Clínic of Barcelona Barret L, et al. The clinical presentation of prosthetic joint infection. J Antimicrob

More information

Technical aspects of RRT in AKI: access, anticoagulation, drug dosage and nutrition. Marlies Ostermann

Technical aspects of RRT in AKI: access, anticoagulation, drug dosage and nutrition. Marlies Ostermann Technical aspects of RRT in AKI: access, anticoagulation, drug dosage and nutrition Marlies Ostermann AKI guideline Chapter 3: Nutrition Chapter 5.3: Anticoagulation Chapter 5.4: Vascular access for RRT

More information

NEW DEVELOPMENTS AND CHALLENGING CASES IN HOSPITAL INFECTIOUS DISEASES

NEW DEVELOPMENTS AND CHALLENGING CASES IN HOSPITAL INFECTIOUS DISEASES Lisa G. Winston, MD Professor, University of California, San Francisco Vice Chief, Inpatient Medical Services and Hospital Epidemiologist, San Francisco General Hospital NEW DEVELOPMENTS AND CHALLENGING

More information

Treatment Strategies for Infections due to MDR-GNR

Treatment Strategies for Infections due to MDR-GNR Treatment Strategies for Infections due to MDR-GNR Michael Satlin, MD Instructor in Medicine Division of Infectious Diseases Weill Cornell Medical College, New York, NY October 16, 2012 1 2 Faculty Disclosure

More information

Optimization of anti-infective dosing regimens during online haemodiafiltration Jager, Nynke G L; Zandvliet, Anthe S; Touw, Daniël; Penne, Erik L

Optimization of anti-infective dosing regimens during online haemodiafiltration Jager, Nynke G L; Zandvliet, Anthe S; Touw, Daniël; Penne, Erik L University of Groningen Optimization of anti-infective dosing regimens during online haemodiafiltration Jager, Nynke G L; Zandvliet, Anthe S; Touw, Daniël; Penne, Erik L Published in: Clinical Kidney Journal

More information

The CLSI Approach to Setting Breakpoints

The CLSI Approach to Setting Breakpoints The CLSI Approach to Setting Breakpoints Jean B. Patel, PhD, D(ABMM) Deputy Director, Office of Antimicrobial Resistance Division of Healthcare Quality Promotion National Center for Emerging and Zoonotic

More information

Impact of hospital guideline for weight-based antimicrobial dosing in morbidly obese adults and comprehensive literature review

Impact of hospital guideline for weight-based antimicrobial dosing in morbidly obese adults and comprehensive literature review Journal of Clinical Pharmacy and Therapeutics, 2014, 39, 584 608 doi: 10.1111/jcpt.12200 Review Article Impact of hospital guideline for weight-based antimicrobial dosing in morbidly obese adults and comprehensive

More information

July 2011 IN THIS ISSUE:

July 2011 IN THIS ISSUE: July 2011 IN THIS ISSUE: Mass Spectrometry Pg 2 VITEK 2 PC5.01 Pg 3 Henry Ford Hospital Pg 5 ProLab Pg 6 New VITEK 2 Cards Pg 8 Total AST Pg 11 Events Calendar Pg 12 Mass Spectrometry: Cutting Edge Microbial

More information

Disclosure. Objectives. Evolution of β Lactamases. Extended Spectrum β Lactamases: The New Normal. Prevalence of ESBL Mystic Program

Disclosure. Objectives. Evolution of β Lactamases. Extended Spectrum β Lactamases: The New Normal. Prevalence of ESBL Mystic Program 47 th Annual Meeting August 2-4, 2013 Orlando, FL Extended Spectrum β Lactamases: The New Normal Disclosure I do have a vested interest in or affiliation with the following companies or organizations Triax

More information

Pneumonia: The Forgotten Killer

Pneumonia: The Forgotten Killer Pneumonia: The Forgotten Killer David Glenn Weismiller, MD, ScM, FAAFP Department of Family and Community Medicine University of Nevada, Las Vegas School of Medicine Disclosure Statement It is the policy

More information

ESCMID Online Lecture Library. by author

ESCMID Online Lecture Library. by author Disclosures Pk/Pd of antifungal drugs Johan W. Mouton MD PhD FIDSA Professor pharmacokinetics and pharmacodynamics Research grants advisory boards speaker Dosing should be such that the level of antmicrobial

More information

New drugs necessity for therapeutic drug monitoring

New drugs necessity for therapeutic drug monitoring New drugs necessity for therapeutic drug monitoring Stephan Krähenbühl Clinical Pharmacology & Toxicology University Hospital Basel kraehenbuehl@uhbs.ch Drugs suitable for TDM Narrow therapeutic range

More information